Evolution of commercially available compounds for HTS
•A critical assessment of 16 million commercially available compounds.•A comparison of vendors’ offerings.•How the offerings have evolved to meet modern physiochemical requirements.•A selection of 500,000 lead-like compounds that can be sourced from just 6 suppliers. Over recent years, an industry o...
Gespeichert in:
Veröffentlicht in: | Drug discovery today 2019-02, Vol.24 (2), p.390-402 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 402 |
---|---|
container_issue | 2 |
container_start_page | 390 |
container_title | Drug discovery today |
container_volume | 24 |
creator | Volochnyuk, Dmitriy M. Ryabukhin, Sergey V. Moroz, Yurii S. Savych, Olena Chuprina, Alexander Horvath, Dragos Zabolotna, Yuliana Varnek, Alexandre Judd, Duncan B. |
description | •A critical assessment of 16 million commercially available compounds.•A comparison of vendors’ offerings.•How the offerings have evolved to meet modern physiochemical requirements.•A selection of 500,000 lead-like compounds that can be sourced from just 6 suppliers.
Over recent years, an industry of compound suppliers has grown to provide drug discovery with screening compounds: it is estimated that there are over 16 million compounds available from these sources. Here, we review the chemical space covered by suppliers’ compound libraries (SCL) in terms of compound physicochemical properties, novelty, diversity, and quality. We examine the feasibility of compiling high-quality vendor-based libraries avoiding complicated, expensive compound management activity, and compare the resulting libraries to the ChEMBL data set. We also consider how vendors have responded to the evolving requirements for drug discovery.
An assessment of 16 million commercially available compounds, (properties and quality), comparing vendors’ offerings and how they have evolved to meet modern physiochemical requirements. A selection of 500,000 lead-like compounds for high throughput screening. |
doi_str_mv | 10.1016/j.drudis.2018.10.016 |
format | Article |
fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_02347044v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1359644618302423</els_id><sourcerecordid>2130800716</sourcerecordid><originalsourceid>FETCH-LOGICAL-c508t-9146f64f1f601edfb50365a7de409f73437b332f893b0f3eccac5d225c6bf6b23</originalsourceid><addsrcrecordid>eNp9kMtKxDAUQIMovv9ApEtddLx5tt0IIqMjDLhQ1yHNAzOkkzGZDvj3tlZduko4nHsvHIQuMMwwYHGzmpnUG59nBHA9oNkA99Axrqu65DUl-8Of8qYUjIkjdJLzCgCThotDdESBNg1j9Bjx-S6Gfuvjuoiu0LHrbNJehfBZqJ3yQbXBjngT-7XJhYupWLy-nKEDp0K25z_vKXp7mL_eL8rl8-PT_d2y1BzqbdlgJpxgDjsB2BrXcqCCq8pYBo2rKKNVSylxdUNbcNRqrTQ3hHAtWidaQk_R9bT3XQW5Sb5T6VNG5eXibilHBoSyChjb4cG9mtxNih-9zVvZ-axtCGptY58lwRRqgAqLQWWTqlPMOVn3txuDHOPKlZziyjHuSOF77PLnQt921vwN_dYchNtJsEOTnbdJZu3tWlvjk9VbaaL__8IXBRuLFg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2130800716</pqid></control><display><type>article</type><title>Evolution of commercially available compounds for HTS</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Volochnyuk, Dmitriy M. ; Ryabukhin, Sergey V. ; Moroz, Yurii S. ; Savych, Olena ; Chuprina, Alexander ; Horvath, Dragos ; Zabolotna, Yuliana ; Varnek, Alexandre ; Judd, Duncan B.</creator><creatorcontrib>Volochnyuk, Dmitriy M. ; Ryabukhin, Sergey V. ; Moroz, Yurii S. ; Savych, Olena ; Chuprina, Alexander ; Horvath, Dragos ; Zabolotna, Yuliana ; Varnek, Alexandre ; Judd, Duncan B.</creatorcontrib><description>•A critical assessment of 16 million commercially available compounds.•A comparison of vendors’ offerings.•How the offerings have evolved to meet modern physiochemical requirements.•A selection of 500,000 lead-like compounds that can be sourced from just 6 suppliers.
Over recent years, an industry of compound suppliers has grown to provide drug discovery with screening compounds: it is estimated that there are over 16 million compounds available from these sources. Here, we review the chemical space covered by suppliers’ compound libraries (SCL) in terms of compound physicochemical properties, novelty, diversity, and quality. We examine the feasibility of compiling high-quality vendor-based libraries avoiding complicated, expensive compound management activity, and compare the resulting libraries to the ChEMBL data set. We also consider how vendors have responded to the evolving requirements for drug discovery.
An assessment of 16 million commercially available compounds, (properties and quality), comparing vendors’ offerings and how they have evolved to meet modern physiochemical requirements. A selection of 500,000 lead-like compounds for high throughput screening.</description><identifier>ISSN: 1359-6446</identifier><identifier>EISSN: 1878-5832</identifier><identifier>DOI: 10.1016/j.drudis.2018.10.016</identifier><identifier>PMID: 30399443</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Chemical Sciences ; Cheminformatics ; Drug Discovery ; High-Throughput Screening Assays ; Medicinal Chemistry ; Organic chemistry ; Small Molecule Libraries</subject><ispartof>Drug discovery today, 2019-02, Vol.24 (2), p.390-402</ispartof><rights>2019 The Authors</rights><rights>Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c508t-9146f64f1f601edfb50365a7de409f73437b332f893b0f3eccac5d225c6bf6b23</citedby><cites>FETCH-LOGICAL-c508t-9146f64f1f601edfb50365a7de409f73437b332f893b0f3eccac5d225c6bf6b23</cites><orcidid>0000-0001-5382-5215 ; 0000-0002-3795-185X ; 0000-0003-0173-5714 ; 0000-0001-9068-612X ; 0000-0003-1886-925X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.drudis.2018.10.016$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30399443$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-02347044$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Volochnyuk, Dmitriy M.</creatorcontrib><creatorcontrib>Ryabukhin, Sergey V.</creatorcontrib><creatorcontrib>Moroz, Yurii S.</creatorcontrib><creatorcontrib>Savych, Olena</creatorcontrib><creatorcontrib>Chuprina, Alexander</creatorcontrib><creatorcontrib>Horvath, Dragos</creatorcontrib><creatorcontrib>Zabolotna, Yuliana</creatorcontrib><creatorcontrib>Varnek, Alexandre</creatorcontrib><creatorcontrib>Judd, Duncan B.</creatorcontrib><title>Evolution of commercially available compounds for HTS</title><title>Drug discovery today</title><addtitle>Drug Discov Today</addtitle><description>•A critical assessment of 16 million commercially available compounds.•A comparison of vendors’ offerings.•How the offerings have evolved to meet modern physiochemical requirements.•A selection of 500,000 lead-like compounds that can be sourced from just 6 suppliers.
Over recent years, an industry of compound suppliers has grown to provide drug discovery with screening compounds: it is estimated that there are over 16 million compounds available from these sources. Here, we review the chemical space covered by suppliers’ compound libraries (SCL) in terms of compound physicochemical properties, novelty, diversity, and quality. We examine the feasibility of compiling high-quality vendor-based libraries avoiding complicated, expensive compound management activity, and compare the resulting libraries to the ChEMBL data set. We also consider how vendors have responded to the evolving requirements for drug discovery.
An assessment of 16 million commercially available compounds, (properties and quality), comparing vendors’ offerings and how they have evolved to meet modern physiochemical requirements. A selection of 500,000 lead-like compounds for high throughput screening.</description><subject>Chemical Sciences</subject><subject>Cheminformatics</subject><subject>Drug Discovery</subject><subject>High-Throughput Screening Assays</subject><subject>Medicinal Chemistry</subject><subject>Organic chemistry</subject><subject>Small Molecule Libraries</subject><issn>1359-6446</issn><issn>1878-5832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtKxDAUQIMovv9ApEtddLx5tt0IIqMjDLhQ1yHNAzOkkzGZDvj3tlZduko4nHsvHIQuMMwwYHGzmpnUG59nBHA9oNkA99Axrqu65DUl-8Of8qYUjIkjdJLzCgCThotDdESBNg1j9Bjx-S6Gfuvjuoiu0LHrbNJehfBZqJ3yQbXBjngT-7XJhYupWLy-nKEDp0K25z_vKXp7mL_eL8rl8-PT_d2y1BzqbdlgJpxgDjsB2BrXcqCCq8pYBo2rKKNVSylxdUNbcNRqrTQ3hHAtWidaQk_R9bT3XQW5Sb5T6VNG5eXibilHBoSyChjb4cG9mtxNih-9zVvZ-axtCGptY58lwRRqgAqLQWWTqlPMOVn3txuDHOPKlZziyjHuSOF77PLnQt921vwN_dYchNtJsEOTnbdJZu3tWlvjk9VbaaL__8IXBRuLFg</recordid><startdate>201902</startdate><enddate>201902</enddate><creator>Volochnyuk, Dmitriy M.</creator><creator>Ryabukhin, Sergey V.</creator><creator>Moroz, Yurii S.</creator><creator>Savych, Olena</creator><creator>Chuprina, Alexander</creator><creator>Horvath, Dragos</creator><creator>Zabolotna, Yuliana</creator><creator>Varnek, Alexandre</creator><creator>Judd, Duncan B.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0001-5382-5215</orcidid><orcidid>https://orcid.org/0000-0002-3795-185X</orcidid><orcidid>https://orcid.org/0000-0003-0173-5714</orcidid><orcidid>https://orcid.org/0000-0001-9068-612X</orcidid><orcidid>https://orcid.org/0000-0003-1886-925X</orcidid></search><sort><creationdate>201902</creationdate><title>Evolution of commercially available compounds for HTS</title><author>Volochnyuk, Dmitriy M. ; Ryabukhin, Sergey V. ; Moroz, Yurii S. ; Savych, Olena ; Chuprina, Alexander ; Horvath, Dragos ; Zabolotna, Yuliana ; Varnek, Alexandre ; Judd, Duncan B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c508t-9146f64f1f601edfb50365a7de409f73437b332f893b0f3eccac5d225c6bf6b23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Chemical Sciences</topic><topic>Cheminformatics</topic><topic>Drug Discovery</topic><topic>High-Throughput Screening Assays</topic><topic>Medicinal Chemistry</topic><topic>Organic chemistry</topic><topic>Small Molecule Libraries</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Volochnyuk, Dmitriy M.</creatorcontrib><creatorcontrib>Ryabukhin, Sergey V.</creatorcontrib><creatorcontrib>Moroz, Yurii S.</creatorcontrib><creatorcontrib>Savych, Olena</creatorcontrib><creatorcontrib>Chuprina, Alexander</creatorcontrib><creatorcontrib>Horvath, Dragos</creatorcontrib><creatorcontrib>Zabolotna, Yuliana</creatorcontrib><creatorcontrib>Varnek, Alexandre</creatorcontrib><creatorcontrib>Judd, Duncan B.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Drug discovery today</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Volochnyuk, Dmitriy M.</au><au>Ryabukhin, Sergey V.</au><au>Moroz, Yurii S.</au><au>Savych, Olena</au><au>Chuprina, Alexander</au><au>Horvath, Dragos</au><au>Zabolotna, Yuliana</au><au>Varnek, Alexandre</au><au>Judd, Duncan B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evolution of commercially available compounds for HTS</atitle><jtitle>Drug discovery today</jtitle><addtitle>Drug Discov Today</addtitle><date>2019-02</date><risdate>2019</risdate><volume>24</volume><issue>2</issue><spage>390</spage><epage>402</epage><pages>390-402</pages><issn>1359-6446</issn><eissn>1878-5832</eissn><abstract>•A critical assessment of 16 million commercially available compounds.•A comparison of vendors’ offerings.•How the offerings have evolved to meet modern physiochemical requirements.•A selection of 500,000 lead-like compounds that can be sourced from just 6 suppliers.
Over recent years, an industry of compound suppliers has grown to provide drug discovery with screening compounds: it is estimated that there are over 16 million compounds available from these sources. Here, we review the chemical space covered by suppliers’ compound libraries (SCL) in terms of compound physicochemical properties, novelty, diversity, and quality. We examine the feasibility of compiling high-quality vendor-based libraries avoiding complicated, expensive compound management activity, and compare the resulting libraries to the ChEMBL data set. We also consider how vendors have responded to the evolving requirements for drug discovery.
An assessment of 16 million commercially available compounds, (properties and quality), comparing vendors’ offerings and how they have evolved to meet modern physiochemical requirements. A selection of 500,000 lead-like compounds for high throughput screening.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>30399443</pmid><doi>10.1016/j.drudis.2018.10.016</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0001-5382-5215</orcidid><orcidid>https://orcid.org/0000-0002-3795-185X</orcidid><orcidid>https://orcid.org/0000-0003-0173-5714</orcidid><orcidid>https://orcid.org/0000-0001-9068-612X</orcidid><orcidid>https://orcid.org/0000-0003-1886-925X</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1359-6446 |
ispartof | Drug discovery today, 2019-02, Vol.24 (2), p.390-402 |
issn | 1359-6446 1878-5832 |
language | eng |
recordid | cdi_hal_primary_oai_HAL_hal_02347044v1 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Chemical Sciences Cheminformatics Drug Discovery High-Throughput Screening Assays Medicinal Chemistry Organic chemistry Small Molecule Libraries |
title | Evolution of commercially available compounds for HTS |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T23%3A24%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evolution%20of%20commercially%20available%20compounds%20for%20HTS&rft.jtitle=Drug%20discovery%20today&rft.au=Volochnyuk,%20Dmitriy%20M.&rft.date=2019-02&rft.volume=24&rft.issue=2&rft.spage=390&rft.epage=402&rft.pages=390-402&rft.issn=1359-6446&rft.eissn=1878-5832&rft_id=info:doi/10.1016/j.drudis.2018.10.016&rft_dat=%3Cproquest_hal_p%3E2130800716%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2130800716&rft_id=info:pmid/30399443&rft_els_id=S1359644618302423&rfr_iscdi=true |